الفهرس 
Introduction &Aim of the workOnly 14 pages are availabe for public view
 |  | from | 156 |  |  |
| | | from | 156 | | |
Abstract
Mammography, magnetic resonance imaging (MRI) and ultrasound are useful tools that can be used in breast cancer (Br Ca) screening but these methods have various limitations. Thus, finding diagnostic biomarkers may be a useful alternative choice. A total of 142 females with breast diseases (40 females with benign conditions and 102 females with Br Ca) were included in the study. In addition to age- and sex-matched 29 normal females as a negative control. The level of collagen III was detected using the ELISA technique. It was (21.29±3.14 µg/ml) in sera of females with Br Ca higher than in benign (13.91±2.65 µg/ml) and in normal (5.69±0.43 µg/ml) females. Collagen III yielded an AUC of 0.86 to differentiate Br Ca from normal females and an AUC of 0.62 to differentiate Br Ca females from those with benign conditions. Moreover, AUC was risen to 0.72 to differentiate females with Br Ca from those without Br Ca. While the index provided values that were significantly (P<0.01) higher in Br Ca (9.1±1.3) than benign (6.3±1.1) and normal (2.5±1.1) females. It yielded an AUC of 0.98 (sensitivity = 90.0 %) to differentiate Br Ca from normal females and an AUC of 0.84 to differentiate Br Ca females from those with benign conditions. Moreover, AUC was risen to 0.87 to differentiate females with Br Ca from those without Br Ca (sensitivity = 84.0 %). In conclusion, serum collagen III concentration represents a candidate biomarker for Br Ca. Moreover, its combination with cancer antigen 15-3 (CA 15.3) and age provided a valuable index for Br Ca diagnosis with high accuracy.